Phase II study of capecitabine (X) plus docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates.

被引：0
|
作者：
Bellet, M.
Muñoz, M.
Bellosillo, B.
Corominas, J.
Pena, T.
Suárez, M.
Maristany, M.
Perich, J.
Tusquets, I.
Fabregat, X.
机构：
[1] Hosp del Mar, Barcelona, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Roche Farma, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43S / 43S
页数：1
相关论文
共 50 条
  • [1] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.
    Wildiers, H.
    Neven, P.
    Christiaens, M-R
    Fesneaux, G.
    Amant, F.
    Weltens, C.
    Smeets, A.
    van Limbergen, E.
    Debrock, G.
    Renard, V
    Paridaens, R.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 335S - 335S
  • [3] Multicentre phase II study of capecitabine (X), docetaxel (T) trastuzumab (H) as neoadjuvant treatment for patients (PTS) with locally advanced breast cancer (LABC): Preliminary safety and efficacy results
    Lybaert, Willem
    Wildiers, Hans
    Neven, Patrick
    Clement, Paul
    Amant, Frederic
    Christiaens, Marie-Rose
    Van Limbergen, Eric
    Weltens, Caroline
    Drijkoningen, Ria
    Paridaens, Robert
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [4] Neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC):: preliminary safety and efficacy data from a multicentre phase II study
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 157 - 158
  • [5] Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC):: Preliminary safety and efficacy data.
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Clement, P.
    Amant, F.
    Christiaens, M-R
    Smeets, A.
    Van Limbergen, E.
    Weltens, C.
    Drijkoningen, R.
    Debrock, G.
    Paridaens, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S147 - S148
  • [6] Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Christaens, M.-R.
    Weltens, C.
    Drijkonngen, R.
    Van Ongeval, C.
    Van Steen, A.
    Paridaens, R.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 105 - 106
  • [7] Neoadjuvant regimen with epirubicin (E) plus cyclophpsphamide (C) followed by docetaxel (T) plus capecitabine (X) in locally advanced breast cancer (LABC)
    Saracchini, S.
    Boccalon, M.
    Ferlante, M.
    Manocchi, M.
    Rositani, P.
    Sul-faro, S.
    Marus, W.
    Michieli, E.
    Bonamini, M.
    Vaclaw, B.
    Arcicasa, M.
    Roncadin, M.
    Piazza, R.
    Antonimi, Canterin F.
    Tumolo, S.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI13 - XI13
  • [8] Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer
    Pérez-Manga, G
    Méndez, M
    Palomero, MI
    Quibén, R
    Belón, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S230 - S231
  • [9] Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 133 - 133
  • [10] Docetaxel (T) plus capecitabine (X) with or without trastuzumab (H) neoadjuvant therapy for locally advanced breast cancer (BC): Phase II study
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Amant, F.
    Christiaens, M.
    Van Limbergen, E.
    Weltens, C.
    Drijkoningen, R.
    Debrock, G.
    Paridaens, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345